TY - JOUR
T1 - Association of Li-Fraumeni Syndrome with Small Cell Carcinoma of the Ovary, Hypercalcemic Type and Concurrent Pleomorphic Liposarcoma of the Cervix
AU - Tandon, Bevan
AU - Hagemann, Ian S.
AU - Maluf, Horacio M.
AU - Pfeifer, John D.
AU - Al-Kateb, Hussam
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a rare, highly lethal malignancy predominantly affecting young adult females. We report a patient with widely metastatic SCCOHT and concurrent uterine cervical pleomorphic liposarcoma. Clinical targeted next-generation sequencing was performed on both neoplasms and demonstrated hemizygous stop-gain TP53 mutations (p.R196∗), and wild-type SMARCA4 in both tumors. Microarray analyses of both tumors revealed similar but not identical widespread loss of heterozygosity over most chromosomes associated with loss of chromosomal copy number in the SCCOHT and pleomorphic liposarcoma tumors, amplification of FGFR1 in both tumors, and amplification of MYC in the SCCOHT. Immunohistochemistry demonstrated that SMARCA4 and SMARCB1 were retained in both tumors, and that SMARCA2 expression was retained but TP53 expression was lost in the SCCOHT. Germline testing using Sanger sequencing showed heterozygous TP53 mutation, confirming the diagnosis of Li-Fraumeni syndrome. These findings are novel and for the first time associate SCCOHT with Li-Fraumeni syndrome.
AB - Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a rare, highly lethal malignancy predominantly affecting young adult females. We report a patient with widely metastatic SCCOHT and concurrent uterine cervical pleomorphic liposarcoma. Clinical targeted next-generation sequencing was performed on both neoplasms and demonstrated hemizygous stop-gain TP53 mutations (p.R196∗), and wild-type SMARCA4 in both tumors. Microarray analyses of both tumors revealed similar but not identical widespread loss of heterozygosity over most chromosomes associated with loss of chromosomal copy number in the SCCOHT and pleomorphic liposarcoma tumors, amplification of FGFR1 in both tumors, and amplification of MYC in the SCCOHT. Immunohistochemistry demonstrated that SMARCA4 and SMARCB1 were retained in both tumors, and that SMARCA2 expression was retained but TP53 expression was lost in the SCCOHT. Germline testing using Sanger sequencing showed heterozygous TP53 mutation, confirming the diagnosis of Li-Fraumeni syndrome. These findings are novel and for the first time associate SCCOHT with Li-Fraumeni syndrome.
KW - Hypercalcemic type
KW - Li-Fraumeni syndrome
KW - Next-generation sequencing
KW - SMARCA4
KW - Small cell carcinoma of the ovary
KW - TP53
UR - http://www.scopus.com/inward/record.url?scp=85011865877&partnerID=8YFLogxK
U2 - 10.1097/PGP.0000000000000365
DO - 10.1097/PGP.0000000000000365
M3 - Article
C2 - 28177947
AN - SCOPUS:85011865877
SN - 0277-1691
VL - 36
SP - 593
EP - 599
JO - International Journal of Gynecological Pathology
JF - International Journal of Gynecological Pathology
IS - 6
ER -